US-based AbbVie (NYSE: ABBV) announced that it has filed a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for TrenibotE (trenibotulinumtoxinE), a next-generation botulinum toxin type E formulation. The application seeks approval for the treatment of moderate to severe glabellar lines (frown lines between the eyebrows).
Clinical Evidence and Efficacy
The BLA is supported by data from over 2,100 patients across the clinical program, including two pivotal Phase III trials (M21-500 and M21-508) and a Phase III open-label safety study (M21-509). These studies demonstrated rapid onset of action, with effects observed as early as 8 hours post-administration, and sustained efficacy for 2-3 weeks. TrenibotE showed a safety profile comparable to placebo, even with up to three consecutive treatments.
Market Implications
TrenibotE represents a significant advancement in the aesthetic medicine field, offering a new option for patients seeking long-lasting and effective treatment for glabellar lines. The positive Phase III results underscore its potential to reshape the market for botulinum toxin therapies.-Fineline Info & Tech
